Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 4/20 | 0.30 |
| ▸ | DRD4 | P21917 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032907 | 1.00 | ALDH1A1 (0.38) | ALDH1A1POLBSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL25246573 | 0.98 | ALDH1A1 (0.38) | ALDH1A1POLBSMN1; SMN2MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL819402 | 0.98 | ALDH1A1 (0.38) | ALDH1A1POLBSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL28532318 | 0.87 | ALDH1A1 (0.32) | ALDH1A1POLB | |
| SCHEMBL23637519 | 0.74 | ALDH1A1 (0.33) | ALDH1A1POLBSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL283988 | 0.74 | ALDH1A1 (0.52) | ALDH1A1POLBSMN1; SMN2MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL451487 | 0.72 | ALDH1A1 (0.50) | ALDH1A1POLBSMN1; SMN2MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL28554078 | 0.72 | ALDH1A1 (0.50) | ALDH1A1POLBSMN1; SMN2MAPTNPSR1 | |
| Bromide SCHEMBL1608735 | 0.72 | ALDH1A1 (0.50) | ALDH1A1POLBSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL455945 | 0.70 | TP53 (0.36) | ALDH1A1POLBSMN1; SMN2TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-17 | — | — | US | claimed |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-01-07 | — | — | US | claimed |
| US-9072729-B2 | Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-07 | — | — | US | claimed |
| EP-2803356-A1 | Method for treating neurological disorders with imidazolium and imidazolinium compounds | Agency for Science, Technology and Research (SG) | 2014-11-19 | — | — | EP | claimed |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-07-21 | — | — | US | claimed |
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-02-03 | — | — | US | claimed |
| EP-2249832-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | Agency for Science, Technology And Research (SG) | 2010-11-17 | — | — | EP | claimed |
| WO-2009096905-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-08-06 | — | — | WO | claimed |
| US-12559586-B2 | Compositions containing uretdione groups crosslinking at low temperatures | COVESTRO DEUTSCHLAND AG (DE) | 2026-02-24 | — | — | US | disclosed |
| CN-115605525-B | Uretdione-containing compositions that crosslink at low temperatures | 科思创德国股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4157912-B1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-22 | — | — | EP | disclosed |
| EP-3997183-B1 | METHOD FOR THE PRODUCTION OF ISOCYANURATES FROM URETDIONES | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-20230219983-A1 | TETRADENTATE DIAMINODIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX, AND METHOD FOR MANUFACTURING SAME AND APPLICATION FOR SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-07-13 | — | — | US | disclosed |
| US-20230192941-A1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | COVESTRO DEUTSCHLAND AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20140371454-A1 | CATALYSTS FOR EFFICIENT Z-SELECTIVE METATHESIS | TRUSTEES OF BOSTON COLLEGE | 2014-12-18 | — | — | US | disclosed |
| EP-2803356-A1 | Method for treating neurological disorders with imidazolium and imidazolinium compounds | Agency for Science, Technology and Research (SG) | 2014-11-19 | — | — | EP | disclosed |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-07-21 | — | — | US | disclosed |
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-02-03 | — | — | US | disclosed |
| EP-2271338-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | Agency for Science, Technology And Research (SG) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009123569-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559586-B2 | Compositions containing uretdione groups crosslinking at low temperatures | URB2, UQCRB, UQCRC2 | ALDH1A1 1357/4885POLB 2146/4885SMN1; SMN2 4159/4885 |
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | SMN1; SMN2, INA, NLN | ALDH1A1 2486/4885POLB 4811/4885SMN1; SMN2 1/4885 |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | ALDH1A1 1225/4885POLB 4512/4885SMN1; SMN2 2014/4885 |
| US-20230219983-A1 | TETRADENTATE DIAMINODIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX, AND METHOD FOR MANUFACTURING SAME AND APPLICATION FOR SAME | ADH4, ADH5, PF4 | ALDH1A1 219/4885POLB 1823/4885SMN1; SMN2 1672/4885 |
| US-20140371454-A1 | CATALYSTS FOR EFFICIENT Z-SELECTIVE METATHESIS | ADH5, ADH1A, ADH1C | ALDH1A1 21/4885POLB 1672/4885SMN1; SMN2 1849/4885 |
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | ALDH1A1 1225/4885POLB 4512/4885SMN1; SMN2 2014/4885 |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | ALDH1A1 1225/4885POLB 4512/4885SMN1; SMN2 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.